Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.

Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN.

Antimicrob Agents Chemother. 2009 Jun;53(6):2532-8. doi: 10.1128/AAC.01374-08. Epub 2009 Mar 2.

2.

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.

Antivir Ther. 2007;12(4):453-8.

PMID:
17668553
3.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine..

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
6.

Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Micheli V, Regazzi M, Dickinson L, Meraviglia P, Villani P, Khoo SH, Viganò P, Cordier L, Cusato M, Duca P, Orlando G, Rizzardini G, Back DJ, Cargnel A.

Ther Drug Monit. 2008 Jun;30(3):306-13. doi: 10.1097/FTD.0b013e318177209e.

7.

Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B, Valle M.

Clin Pharmacokinet. 2008;47(10):681-92.

PMID:
18783298
8.

Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.

Klinklom A, Puthanakit T, Gorowara M, Phasomsap C, Kerr S, Sriheara C, Ananworanich J, Burger D, Ruxrungtham K, Pancharoen C.

Antivir Ther. 2012;17(2):283-9. doi: 10.3851/IMP1958. Epub 2011 Nov 10.

PMID:
22293065
9.

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-75.

PMID:
15385734
10.

Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW.

Br J Clin Pharmacol. 2005 Apr;59(4):398-404.

11.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M; P1030 team..

AIDS. 2008 Jan 11;22(2):249-55.

PMID:
18097227
12.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.

Int J Antimicrob Agents. 2005 Jul;26(1):88-91.

PMID:
15878262
13.

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10. Epub 2011 May 2.

14.

Lopinavir/ritonavir (ABT-378/r).

Qazi NA, Morlese JF, Pozniak AL.

Expert Opin Pharmacother. 2002 Mar;3(3):315-27. Review.

PMID:
11866671
15.

Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.

Antivir Ther. 2007;12(6):963-9.

PMID:
17926651
16.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
17.

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.

J Clin Virol. 2006 Apr;35(4):414-9. Epub 2005 Nov 8.

PMID:
16280255
18.

Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.

Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, Redfield RR.

AIDS Patient Care STDS. 2006 Nov;20(11):745-59.

PMID:
17134349
19.

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.

González de Requena D, Gallego O, Valer L, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2004 Mar;20(3):275-8.

PMID:
15117450
20.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

Supplemental Content

Support Center